21 results
PRE 14A
TYRA
Tyra Biosciences Inc
5 Apr 24
Preliminary proxy
4:20pm
retirement in June 2020, Mr. Fuhrman served as Chief Financial Officer of Amplyx Pharmaceuticals, Inc. Prior to Amplyx, Mr. Fuhrman served as Chief … of Compensation
Health and Welfare and Retirement Benefits; Perquisites
All of our current named executive officers are eligible to participate in our employee
8-K
EX-10.1
TYRA
Tyra Biosciences Inc
5 Feb 24
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
6:05am
Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”); no “reportable event
S-3
EX-1.2
nnsnpcia
3 Oct 22
Shelf registration
4:05pm
S-3
EX-4.4
nbe6o52p4xfy2zn o469
3 Oct 22
Shelf registration
4:05pm
DEF 14A
0bcy82iupcg4dul3ub
28 Apr 22
Definitive proxy
4:07pm
10-K
EX-10.15
uoltc67
3 Mar 22
Annual report
4:31pm
8-K
EX-3.1
4q089x0
17 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
424B4
dz3s7mt6
15 Sep 21
Prospectus supplement with pricing info
4:10pm
S-1/A
EX-10.2
5atgk2
9 Sep 21
IPO registration (amended)
6:08am
S-1/A
zbj90lo
9 Sep 21
IPO registration (amended)
6:08am
S-1
EX-3.3
v6464i gz9wj
20 Aug 21
IPO registration
4:07pm
S-1
EX-10.1
xlp8hbfim
20 Aug 21
IPO registration
4:07pm
S-1
vxn6fbmjsrv7vwkkzob
20 Aug 21
IPO registration
4:07pm
S-1
EX-10.19
36hu2vl
20 Aug 21
IPO registration
4:07pm
DRS/A
EX-10.1
30savk
2 Jul 21
Draft registration statement (amended)
12:00am
DRS/A
b1e s1qeem
2 Jul 21
Draft registration statement (amended)
12:00am